Volume 1 | Issue 4 | DOI: https://doi.org/10.33696/Gastroenterology.1.016
The Dual Role of Macrophages during Hepatitis B Infection
- 1Division of Chronic Inflammation and Cancer, German Cancer Research Centre (DKFZ), 69120, Heidelberg, Germany
- 2INSERM, U1052, Cancer Research Centre of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France
Faure-Dupuy Suzanne, firstname.lastname@example.org
Received Date: October 05, 2020
Accepted Date: October 20, 2020
Faure-Dupuy S, Lucifora J, Durante D. The Dual Role of Macrophages during Hepatitis B Infection. Arch Gastroenterol Res. 2020; 1(4): 89-94.
Copyright: © 2020 Faure-Dupuy S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Macrophages, and related cells, are key players of the innate immune response against pathogens. However, they can also be implicated in pathogen persistence and associated pathogenesis. Hereby, we discussed the dual role of liver macrophages during Hepatitis B virus infection. Whereas pro-inflammatory macrophage secretions can inhibit the viral infection, modulation of macrophages phenotype by the virus favour the establishment and maintenance of the infection.
Hepatitis B virus, Pro-inflammatory macrophage, Anti-inflammatory macrophage, Immune modulation, Kupffer cells, IL-1beta, Primary cells, Anti-viral
Hepatitis B virus (HBV) chronically infects more than 250 million individuals worldwide and is responsible for more than 800,000 deaths per year by promoting end-stage liver diseases, among which decompensated cirrhosis and hepatocellular carcinoma (HCC) (WHO, July 2020) are prominent. Studies performed in chimpanzees or in animalversion of HBV (woodchuck HBV: WHBV) highlighted the lack of immune responses against the virus upon primary infection. Thus, HBV has been described as a “stealth” virus (i.e. a virus that does not modify/induce immune response in the cell). However, a growing number of studies describe that HBV is able to rapidly and efficiently counteract the innate immune response in a large variety of cells (hepatocytes, macrophages, Natural Killer cell…). Hereby, we focus on the role of macrophages (Mφ) during HBV infection.
What Can Go Wrong When Applying Immune Modulation Therapies to Target Persistent Bacterial Infections
Persistence is a transient phenotypic adaptation that confers survival to a small percentage of cells (between 0.01 and 10%) in genetically identical bacterial populations. Nevertheless, persistence greatly affects the evolution of acquired drug resistance mutations by decreasing antibiotic efficacy and generating a reservoir of surviving cells that can contribute to the onset of chronic infectious disease.
Are We Close to Achieving a HBV Cure? Risk for Hepatocellular Carcinoma Persists Despite Long-term HBV Suppression: An Update on Our Experience
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al., great progress has been made in understanding the pathogenesis of the virus and its role in hepatocellular carcinoma (HCC). It is estimated that hepatitis B is responsible for about 50% of the HCC cases worldwide. Because of geographic variations in HBV incidence, the burden of HBV-related HCC (HBV-HCC) is highest in endemic areas such as Asian-Pacific and sub- Saharan Africa and lowest in the United States and the West. The hepatitis B vaccines, developed in the 1980s, transformed the evolution of hepatitis B in the modern era. This was followed by high effective anti-viral that reduced HBV infections and HBV-HCC.
Tenofovir, alias (R)-PMPA, was first divulged as an anti- HIV agent in 1993 . That it would in 2012, become the first antiretroviral agent, approved by the US FDA (Food and Drug Administration) to prevent HIV infection, could have been predicted from the findings of Tsai et al.
Using Intralipid to Improve Delivery of Anti-Cancer Nanodrugs: Effects on RES Clearance and Toxi city, EPR, and Immune Modulation
Encapsulation of therapeutic molecules (e.g., small molecule inhibitors, mRNA, siRNA, aptamers, etc.) into nanomaterials can improve the solubility and blood circulation of the drugs, alter their biodistribution, decrease their toxicities, overcome drug resistance, and facilitate their entry into target cells. The development of anti-cancer nanodrugs has been the focus of intense study for decades. Several anti-cancer nanodrugs have been approved for clinical use all over the world.